BofA Downgrades Elevance Health On Medicaid Pressure And Lowered Peer Valuations
Wednesday, Elevance Health Inc. (NYSE:ELV) reported second-quarter revenues of $43.2 billion, down 0.4% year-over-year, marginally above the consensus of $43.05 billion.
The decrease was driven by attrition in Medicaid membership, partially offset by higher premium yields reflecting the medical cost trend.
In the second quarter, UnitedHealth Group Inc (NYSE:UNH) and Elevance Health reported increasing pressure on Medicaid, creating uncertainty about when Medicaid margins will bottom out and when a potential recovery might occur.
Centene Inc. (NYSE:CNC), Cigna Corp (NYSE:CI), and Molina Healthcare Inc. (NYSE:MOH) are trading at a 3x lower valuation than Elevance Health. While Elevance Health’s diversification and quality …
Full story available on Benzinga.com
Related posts:
- Home Run To Homewrecker – Analyst Cautious On Homebuilders, Downgrades Key Players
- Aclaris Therapeutics’ ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
- Archer-Daniels-Midland’s Financial Figures ‘Are Too High,’ Analyst Downgrades Stock
- After 130% Surge, AMD Faces Uncertain Road Ahead: Top Analyst Says Chipmaker’s Future Shrouded In Doubt